Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening
Shots: Idorsia to receive $45M upfront in cash, $365M for development & regulatory milestone, one-time sales threshold and royalties on sales. Additionally, will receive $7M in funding to discover, identify and develop additional novel T-type calcium channel blockers Neurocrine exercises its option to license rights for ACT-709478 (post IND acceptance from the US FDA on […]Read More
